The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pembrolizumab in previously treated metastatic esophageal cancer: Longer term follow-up from the phase 2 KEYNOTE-180 Study.
 
Ken Kato
Consulting or Advisory Role - BeiGene; MSD; Oncolys BioPharma; Oncolys BioPharma; Ono Pharmaceutical
Research Funding - Beigene (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst)
 
Takashi Kojima
Honoraria - Oncolys BioPharma
Research Funding - Astellas Amgen BioPharama (Inst); MSD (Inst); Oncolys BioPharma (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst)
 
Daniel Hochhauser
Stock and Other Ownership Interests - Novartis; Roche
Research Funding - Merck Serono
Travel, Accommodations, Expenses - Celgene
 
Jaafar Bennouna
Honoraria - Boehringer Ingelheim; Novartis; Pierre Fabre; roche
Consulting or Advisory Role - Boehringer Ingelheim; Novartis; Pierre Fabre; Roche
 
Antoine Hollebecque
Honoraria - Merck Serono
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune (Inst); Gritstone Bio; Incyte (Inst); Lilly (Inst); Spectrum Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Lilly; SERVIER
Other Relationship - Abbvie; Agios; Amgen; argenx; Arno Therapeutics; Astex Pharmaceuticals; AstraZeneca; AVEO; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Clovis Oncology; Daiichi Sankyo; Debiopharm Group; Eisai; Exelixis; FORMA Therapeutics; GamaMabs Pharma; Genentech; GlaxoSmithKline; H3 Biomedicine; Innate Pharma; Janssen-Cilag; Kyowa Hakko Kirin; Lilly; Loxo; Lytix Biopharma; MedImmune; Menarini; Merck Sharp & Dohme; Merrimack; Merus; Millenium Pharamceuticals; Nanobiotix; Nektar; Novartis; Octimet; Oncoethix; Onyx; Orion; Oryzon Genomics; Pfizer; Pierre Fabre; Roche; Roche/Genentech; Sanofi/Aventis; SERVIER; Taiho Pharmaceutical; Tesaro; Xencor
 
Florian Lordick
Honoraria - AstraZeneca; BioNTech; Bristol-Myers Squibb; Elsevier; Infomedica; Lilly; Merck KGaA; Merck Sharp & Dohme; Roche; SERVIER
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; SERVIER
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly
 
Sung-Bae Kim
Consulting or Advisory Role - Enzychem Lifesciences (Inst); Lilly (Inst); Novartis (Inst); Odonate Therapeutics (Inst)
Research Funding - Dongkook Pharma (Inst); Genzyme (Inst); Novartis (Inst)
 
Masahiro Tajika
Speakers' Bureau - EA Pharma; Nihonkayaku; Olympus Medical Systems
Research Funding - EA Pharma (Inst)
 
Heung Tae Kim
No Relationships to Disclose
 
Haeseong Park
Research Funding - Ambrx (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Roche (Inst); Taiho Pharmaceutical (Inst); Vertex (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - Bayer
 
Nabil F. Saba
Honoraria - Bristol-Myers Squibb; Lilly; Merck; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly; Merck; Pfizer
Research Funding - Bristol-Myers Squibb; Exelixis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck; Pfizer
 
Susan Urba
Honoraria - HERON; Merck
Consulting or Advisory Role - HERON; Merck
Research Funding - Merck
Travel, Accommodations, Expenses - HERON; Merck
 
Anjali Desai
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Qi Liu
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Sandra Cruz
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Manish A. Shah
Consulting or Advisory Role - Astellas Pharma
Research Funding - Boston Biomedical (Inst); Gilead Sciences (Inst); Merck (Inst); Oncolys BioPharma (Inst)